Comment
doi: 10.1016/S2352-3018(22)00375-7.
Lenacapavir in first-line therapy
Affiliations
- PMID: 36566080
- DOI: 10.1016/S2352-3018(22)00375-7
Item in Clipboard
Comment
Lenacapavir in first-line therapy
Lancet HIV.
2023 Jan.
No abstract available
Conflict of interest statement
CO has received research grants to their institution from Gilead Sciences, Viiv Healthcare, MSD, Janssen Pharmaceuticals and Astra Zeneca and has received honoraria and travel scholarships from Gilead Sciences, Viiv Healthcare, MSD, Janssen Pharmaceuticals.
Comment on
-
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0. Lancet HIV. 2023. PMID: 36566079 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
